{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:08:42Z","timestamp":1793851722111,"version":"4.6.1"},"reference-count":340,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijbiomac.2024.137836","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:34:33Z","timestamp":1732811673000},"page":"137836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"P2","title":["The dual role of toll-like receptors in COVID-19: Balancing protective immunity and immunopathogenesis"],"prefix":"10.1016","volume":"284","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-3976","authenticated-orcid":false,"given":"Payam","family":"Behzadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjib","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guttula","family":"Saikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7469-4752","authenticated-orcid":false,"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-9190","authenticated-orcid":false,"given":"Suprabhat","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meysam","family":"Sarshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2024.137836_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000503030","article-title":"Innate immune evasion by human respiratory RNA viruses","volume":"12","author":"Kikkert","year":"2020","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108929","article-title":"Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study","volume":"235","author":"Alseoudy","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0015","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00028-20","article-title":"Coronavirus disease 2019\u2013COVID-19","volume":"33","author":"Dhama","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0020","first-page":"28","article-title":"Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019","volume":"14","author":"Chang","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0025","author":"National Health Commission of the People'\u2019s Republic of China"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0030","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.137836_bb0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.30699\/ijmm.14.4.342","article-title":"Investigation of antiviral drugs with direct effect on RNA polymerases and simulation of their binding to SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase by molecular docking method","volume":"14","author":"Heydargoy","year":"2020","journal-title":"Iran. J. Med. Microbiol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0045","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.3390\/ijerph17165648","article-title":"The global emergency of novel coronavirus (SARS-CoV-2): an update of the current status and forecasting","volume":"17","author":"Hozhabri","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0050","author":"WHO"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0065","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0070","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/v13112132","article-title":"Current understanding of the innate control of toll-like receptors in response to SARS-CoV-2 infection","volume":"13","author":"Jung","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0075","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3390\/ijms22030992","article-title":"Can SARS-CoV-2 virus use multiple receptors to enter host cells?","volume":"22","author":"Gadanec","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0080","doi-asserted-by":"crossref","DOI":"10.7150\/ijbs.45134","article-title":"COVID-19: what has been learned and to be learned about the novel coronavirus disease","volume":"16","author":"Yi","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of genetic variants among young men with severe COVID-19","volume":"324","author":"Van Der Made","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0090","series-title":"Thirty Years since the Discovery of Toll-Like Receptors","article-title":"Toll-like receptors and emerging viral infections","author":"Luqman","year":"2024"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0095","first-page":"1","article-title":"Disengaging the COVID-19 clutch as a discerning eye over the inflammatory circuit during SARS-CoV-2 infection","author":"Anwar","year":"2022","journal-title":"Inflammation"},{"issue":"16","key":"10.1016\/j.ijbiomac.2024.137836_bb0100","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2174\/1389557522666220201154845","article-title":"SARS-CoV-2 infections, impaired tissue, and metabolic health: pathophysiology and potential therapeutics","volume":"22","author":"Singh","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0105","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1007\/s11033-022-07171-0","article-title":"Anti-hyperglycemic effects of Eryngium billardierei F. Delaroche extract on insulin-resistance HepG2 cells in vitro","volume":"49","author":"Kheirollahzadeh","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5578284","article-title":"COVID-19 impact on public health, environment, human psychology, global socioeconomy, and education","volume":"2022","author":"Miyah","year":"2022","journal-title":"Scientific World Journal"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cmi.2021.05.022","article-title":"Novel SARS-CoV-2 variants: the pandemics within the pandemic","volume":"27","author":"Boehm","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/tropicalmed7110373","article-title":"Global distribution, dispersal patterns, and trend of several omicron subvariants of SARS-CoV-2 across the globe","volume":"7","author":"Kopsidas","year":"2022","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2065824","article-title":"Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the omicron variant and increasing COVID-19 cases: an update","volume":"18","author":"Mohapatra","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0130","series-title":"Subvariant \u2018soup\u2019may Drive Wave","author":"Wong","year":"2022"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jiph.2022.11.024","article-title":"Global emerging omicron variant of SARS-CoV-2: impacts, challenges and strategies","volume":"16","author":"Dhama","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0140","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1080\/21645515.2021.1923350","article-title":"Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies","volume":"17","author":"Sharun","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0145","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1080\/21645515.2021.1963601","article-title":"Impact of SARS-CoV-2 delta variant (B. 1.617. 2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic","volume":"17","author":"Tareq","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0150","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40200-022-01002-6","article-title":"Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview","volume":"21","author":"Hadizadeh","year":"2022","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.112816","article-title":"Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic","volume":"209","author":"Khandia","year":"2022","journal-title":"Environ. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chom.2022.11.012","article-title":"Enhanced neutralization resistance of SARS-CoV-2 omicron subvariants BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2","volume":"31","author":"Qu","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0165","article-title":"The SARS-CoV-2 omicron recombinant subvariants XBB, XBB. 1 and XBB1. 5 are expanding rapidly with unique mutations, antibody evasion and immune escape properties-an alarming global threat of surge in COVID-19 cases again?","volume":"10","author":"Chakraborty","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/v15010167","article-title":"A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies","volume":"15","author":"Chatterjee","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0175","article-title":"7 Omicron subvariant (BA. 5.2. 1.7) posing fears of rise in COVID-19 cases again: critical appraisal and salient counteracting strategies","volume":"10","author":"Dhama","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0180","author":"WHO"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0185","first-page":"1","article-title":"Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from alpha to omicron","author":"Chakraborty","year":"2022","journal-title":"GeroScience"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0190","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines","volume":"54","author":"Fernandes","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/cbdd.14035","article-title":"SARS-CoV-2 and its variants of concern including omicron: A never ending pandemic","volume":"99","author":"Mohapatra","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0200","doi-asserted-by":"crossref","first-page":"e00014","DOI":"10.1128\/cmr.00014-22","article-title":"Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 omicron variant","volume":"35","author":"Zhou","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1473-3099(22)00816-7","article-title":"Humoral immune evasion of the omicron subvariants BQ. 1.1 and XBB","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0210","series-title":"Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19)","author":"Aleem","year":"2021"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0215","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 vaccines\u2014immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12257-022-0188-4","article-title":"Current updates on COVID-19 vaccines and therapeutics: As of June 2022","volume":"27","author":"Lee","year":"2022","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0225","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s43440-022-00388-7","article-title":"Oral antiviral treatments for COVID-19: opportunities and challenges","volume":"74","author":"Rahmah","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-023-01973-9","article-title":"An overview on the treatments and prevention against COVID-19","volume":"20","author":"Panahi","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1556\/1886.2021.00020","article-title":"Worldwide protein data Bank (wwPDB): A virtual treasure for research in biotechnology","volume":"11","author":"Behzadi","year":"2022","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782506","article-title":"In silico analyses on the comparative potential of therapeutic human monoclonal antibodies against newly emerged SARS-CoV-2 variants bearing mutant spike protein","volume":"12","author":"Das","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antib12010017","article-title":"Comparative binding ability of human monoclonal antibodies against omicron variants of SARS-CoV-2: an in silico investigation","volume":"12","author":"Das","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14760584.2022.1997601","article-title":"Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants","volume":"21","author":"Chatterjee","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0255","first-page":"1","article-title":"SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies","author":"Gong","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0260","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14760584.2022.2110075","article-title":"Vaccines against SARS-CoV-2 variants and future pandemics","volume":"21","author":"Park","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106233","article-title":"Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: a review article","volume":"98","author":"Saied","year":"2022","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0270","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/vaccines11020332","article-title":"A clinical insight on new discovered molecules and repurposed drugs for the treatment of COVID-19","volume":"11","author":"Banerjee","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0275","article-title":"From immunogen to COVID-19 vaccines: prospects for the post-pandemic era","volume":"114208","author":"Miao","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb0285","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jmv.26387","article-title":"Targeting human TLRs to combat COVID-19: A solution?","volume":"93","author":"Patra","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0290","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/fvl-2021-0249","article-title":"Toll-like receptor 4 in COVID-19: friend or foe?","volume":"17","author":"Mukherjee","year":"2022","journal-title":"Future Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0295","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.humimm.2021.05.001","article-title":"Chemotherapy vs. immunotherapy in combating nCOVID19: an update","volume":"82","author":"Choudhury","year":"2021","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0300","series-title":"Computational Intelligence Techniques for Combating COVID-19","first-page":"45","article-title":"Applications of artificial intelligence (AI) protecting from COVID-19 pandemic: A clinical and socioeconomic perspective","author":"Patra","year":"2021"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0305","series-title":"Toll-Like Receptors and COVID-19: A Two-Faced Story with an Exciting Ending","author":"Onofrio","year":"2020"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0310","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9914854","article-title":"Toll-like receptors: general molecular and structural biology","volume":"2021","author":"Behzadi","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0315","series-title":"Genetic Polymorphism and Cancer Susceptibility","first-page":"281","article-title":"The role of Toll-like receptor (TLR) polymorphisms in urinary bladder cancer","author":"Behzadi","year":"2021"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0320","first-page":"404","article-title":"The role of toll-like receptors (TLRs) in urinary tract infections (UTIs)","volume":"69","author":"Behzadi","year":"2016","journal-title":"Cent. Eur. J. Urol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0325","series-title":"GMS Hygiene and Infection Control","article-title":"Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count","volume":"14","author":"Behzadi","year":"2019"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0330","series-title":"Genetic Polymorphism and Disease","first-page":"379","article-title":"Toll-Like Receptor (TLR) polymorphisms in prostate cancer","author":"Behzadi","year":"2022"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01979","article-title":"Innate immune responses to highly pathogenic coronaviruses and other significant respiratory viral infections","volume":"11","author":"Ahmed-Hassan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0340","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bjid.2015.10.011","article-title":"TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review","volume":"20","author":"Mukherjee","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0345","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12771","article-title":"Toll-like receptor polymorphism in host immune response to infectious diseases: A review","volume":"90","author":"Mukherjee","year":"2019","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1244345","article-title":"Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives","volume":"14","author":"Mukherjee","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294869","article-title":"The innate and adaptive immune system in human urinary system","volume":"14","author":"Behzadi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.599083","article-title":"Toll-like receptor agonists as adjuvants for allergen immunotherapy","volume":"11","author":"Kirtland","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0365","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the aging immune system","volume":"1","author":"Bartleson","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0370","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0375","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2018.08.015","article-title":"Strategies for immune evasion by human tumor viruses","volume":"32","author":"Bussey","year":"2018","journal-title":"Curr. Opin. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0380","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/antibiotics13030257","article-title":"Pan-genome plasticity and virulence factors: A natural treasure trove for Acinetobacter baumannii","volume":"13","author":"Karampatakis","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0385","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0390","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2054431","article-title":"The Interleukin-1 (IL-1) superfamily cytokines and their single nucleotide polymorphisms (SNPs)","volume":"2022","author":"Behzadi","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0395","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/v14071349","article-title":"Coronaviral infection and interferon response: the virus-host arms race and COVID-19","volume":"14","author":"Liu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41427-020-00275-8","article-title":"Molecular recognition in the infection, replication, and transmission of COVID-19-causing SARS-CoV-2: an emerging interface of infectious disease, biological chemistry, and nanoscience","volume":"13","author":"Kumar","year":"2021","journal-title":"NPG Asia Mater."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0405","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cid\/ciaa410","article-title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19","volume":"71","author":"Chu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0410","first-page":"1","article-title":"Clinical trials for the prevention and treatment of coronavirus disease 2019 (COVID-19): the current state of play","author":"Davis","year":"2020","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0415","series-title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)","author":"Ahn","year":"2020"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0420","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0425","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.137836_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26577","article-title":"SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors","volume":"10","author":"Behboudi","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.137836_bb0435","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11262-021-01869-2","article-title":"Host proviral and antiviral factors for SARS-CoV-2","volume":"57","author":"Lv","year":"2021","journal-title":"Virus Genes"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0440","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104833","article-title":"Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor","volume":"157","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0450","series-title":"Lung Microenvironment Plays a Key Role on the Protective vs. Detrimental Effects of Mesenchymal Stromal Cell Therapy in Acute Lung Injury","author":"Islam","year":"2017"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0455","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","article-title":"Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation","volume":"94","author":"Liu","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0460","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol.: A Journal of the Pathological Society of Great Britain and Ireland"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0465","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/cvr\/cvaa078","article-title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2","volume":"116","author":"Chen","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0470","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune determinants of COVID-19 disease presentation and severity","volume":"27","author":"Brodin","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0475","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4324-2023220261","article-title":"SARS-CoV-2 variants impact on key signaling pathways metamorphoses into severity","volume":"66","author":"Misra","year":"2023","journal-title":"Braz. Arch. Biol. Technol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0480","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s11033-022-08188-1","article-title":"Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication","volume":"50","author":"Khalid","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114173","article-title":"mTOR in metabolic homeostasis and disease","volume":"441","author":"Liu","year":"2024","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0490","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0495","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0500","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jmii.2020.04.015","article-title":"ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome","volume":"53","author":"Devaux","year":"2020","journal-title":"J. Microbiol. Immunol. Infect. = Wei mian yu gan ran za zhi"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0505","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s42003-021-02030-3","article-title":"Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2","volume":"4","author":"Suryamohan","year":"2021","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009225","article-title":"SARS-CoV-2 tropism, entry, replication, and propagation: considerations for drug discovery and development","volume":"17","author":"Murgolo","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107587","article-title":"Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients","volume":"213","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.137836_bb0520","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1074\/jbc.M508381200","article-title":"SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells","volume":"281","author":"Huang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"33","key":"10.1016\/j.ijbiomac.2024.137836_bb0525","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0530","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.137836_bb0535","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","article-title":"The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets","volume":"6","author":"Peacock","year":"2021","journal-title":"Nat. Microbiol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.137836_bb0540","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10311-021-01211-0","article-title":"Should we discount the laboratory origin of COVID-19?","volume":"19","author":"Segreto","year":"2021","journal-title":"Environ. Chem. Lett."},{"issue":"7849","key":"10.1016\/j.ijbiomac.2024.137836_bb0545","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","article-title":"Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis","volume":"591","author":"Johnson","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009246","article-title":"Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion","volume":"17","author":"Papa","year":"2021","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.137836_bb0555","doi-asserted-by":"crossref","first-page":"457","DOI":"10.33549\/physiolres.934896","article-title":"The effects of different types of exercise on circulating Irisin levels in healthy individuals and in people with overweight, metabolic syndrome and type 2 diabetes","volume":"71","author":"Parada-S\u00e1nchez","year":"2022","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1208000","article-title":"Editorial: inter-organ communication beyond mammals: the role of tissue-specific cytokines","volume":"14","author":"V\u00e9lez","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0565","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1055\/s-0040-1716379","article-title":"Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients","volume":"4","author":"Tiscia","year":"2020","journal-title":"TH open: Companion Journal to Thrombosis and Haemostasis"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0570","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0575","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0580","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-020-0732-3","article-title":"Immune-mediated approaches against COVID-19","volume":"15","author":"Florindo","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0585","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.4049\/jimmunol.0901888","article-title":"Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling","volume":"184","author":"Guan","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0590","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4049\/jimmunol.174.5.2942","article-title":"Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88","volume":"174","author":"Hasan","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7119","article-title":"Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases","volume":"6","author":"Kanno","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0600","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1128\/JVI.76.17.8729-8736.2002","article-title":"Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling","volume":"76","author":"Bieback","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0605","doi-asserted-by":"crossref","first-page":"11160","DOI":"10.1128\/JVI.03099-12","article-title":"Rotavirus NSP4 triggers secretion of proinflammatory cytokines from macrophages via toll-like receptor 2","volume":"87","author":"Ge","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0610","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/80833","article-title":"Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus","volume":"1","author":"Kurt-Jones","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0615","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00109-004-0620-6","article-title":"Reading the viral signature by toll-like receptors and other pattern recognition receptors","volume":"83","author":"Mogensen","year":"2005","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112622","article-title":"Chemical reagents modulate nucleic acid-activated toll-like receptors","volume":"147","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116281","article-title":"Differential host responses to COVID-19: unraveling the complexity","volume":"109","author":"Verma","year":"2024","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00284-022-03094-y","article-title":"Structural profiles of SARS-CoV-2 variants in India","volume":"80","author":"Chakraborti","year":"2022","journal-title":"Curr. Microbiol."},{"issue":"7835","key":"10.1016\/j.ijbiomac.2024.137836_bb0635","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0640","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15585\/mmwr.mm7003e2","article-title":"Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020\u2013January 12, 2021","volume":"70","author":"Galloway","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.137836_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10111926","article-title":"The Delta and omicron variants of SARS-CoV-2: what we know so far","volume":"10","author":"Chavda","year":"2022","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.137836_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01256-23","article-title":"Analysis of SARS-CoV-2 isolates, namely the Wuhan strain, Delta variant, and Omicron variant, identifies differential immune profiles","volume":"11","author":"Shahbaz","year":"2023","journal-title":"Microbiol. Spectr."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.137836_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23115966","article-title":"Could a lower toll-like receptor (TLR) and NF-\u03baB activation due to a changed charge distribution in the spike protein be the reason for the lower pathogenicity of omicron?","volume":"23","author":"Kircheis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.137836_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105451","article-title":"In silico analyses indicate a lower potency for dimerization of TLR4\/MD-2 as the reason for the lower pathogenicity of omicron compared to wild-type virus and earlier SARS-CoV-2 variants","volume":"25","author":"Kircheis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.137836_bb0665","doi-asserted-by":"crossref","first-page":"316","DOI":"10.31083\/j.fbl2711316","article-title":"Comparison of the pathogenicity of SARS-CoV-2 Delta and Omicron variants by analyzing the expression patterns of immune response genes in K18-hACE2 transgenic mice","volume":"27","author":"Kuruppuarachchi","year":"2022","journal-title":"Front. Biosci. (Landmark edition)"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1231576","article-title":"SARS-CoV-2 omicron variant infection affects blood platelets, a comparative analysis with Delta variant","volume":"14","author":"Garcia","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.137836_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104759","article-title":"SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production","volume":"25","author":"Ao","year":"2022","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgeb.2023.100347","article-title":"SARS-CoV-2 omicron spike shows strong binding affinity and favourable interaction landscape with the TLR4\/MD2 compared to other variants","volume":"22","author":"Chakraborty","year":"2024","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199134","article-title":"SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells","volume":"332","author":"Gori Savellini","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0690","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0274-2021","article-title":"Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell","volume":"31","author":"Girkin","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/030.63.2016.1.1","article-title":"IL-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and signalling pathways","volume":"63","author":"Behzadi","year":"2016","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583373","article-title":"The inflammasome in times of COVID-19","volume":"11","author":"de Rivero Vaccari","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0705","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.137836_bb0710","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.ymthe.2022.02.014","article-title":"The battle between host and SARS-CoV-2: innate immunity and viral evasion strategies","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103153","article-title":"Prophylactic intranasal administration of a TLR2\/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model","volume":"63","author":"Proud","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0720","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00638-15","article-title":"Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection","volume":"6","author":"Totura","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020053","article-title":"Detrimental contribution of the toll-like receptor (TLR) 3 to influenza A virus\u2013induced acute pneumonia","volume":"2","author":"Goffic","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0730","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4049\/jimmunol.176.3.1937","article-title":"Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection","volume":"176","author":"Rudd","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002070","article-title":"MDA5 and TLR3 initiate pro-inflammatory signaling pathways leading to rhinovirus-induced airways inflammation and hyperresponsiveness","volume":"7","author":"Wang","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0740","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.immuni.2011.03.027","article-title":"DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells","volume":"34","author":"Zhang","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0745","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10875-020-00933-0","article-title":"IFN-\u03b12a therapy in two patients with inborn errors of TLR3 and IRF3 infected with SARS-CoV-2","volume":"41","author":"L\u00e9vy","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0750","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0755","first-page":"102","article-title":"Variant rs4986790 of toll-like receptor 4 affects the signaling and induces cell dysfunction in patients with severe COVID-19","volume":"138","author":"Flores-Gonzalez","year":"2024","journal-title":"Int. J. Infect. Dis.: IJID: Official Publication of the International Society for Infectious Diseases"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0760","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2136","article-title":"Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review","volume":"30","author":"Giovane","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0775","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201129","article-title":"SARS-CoV-2\u2013triggered neutrophil extracellular traps mediate COVID-19 pathology","volume":"217","author":"Veras","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.921452","article-title":"Immunomodulatory therapies for COVID-19","volume":"9","author":"Mathur","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00974","article-title":"Airway epithelial cell immunity is delayed during rhinovirus infection in asthma and COPD","volume":"11","author":"Veerati","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175169","article-title":"Mast cells promote viral entry of SARS-CoV-2 via formation of chymase\/spike protein complex","volume":"930","author":"Liu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0795","series-title":"Proceedings of the Seminars in Immunopathology","first-page":"529","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","author":"Channappanavar","year":"2017"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0800","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"Cameron","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0805","first-page":"L217","article-title":"The mercurial nature of neutrophils: still an enigma in ARDS?","volume":"306","author":"Williams","year":"2014","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.137836_bb0810","first-page":"1869","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"30","author":"Chi Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.137836_bb0815","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jsps.2020.08.024","article-title":"Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective","volume":"28","author":"Alnefaie","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0820","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaci.2018.10.054","article-title":"Mast cells as protectors of health","volume":"144","author":"Dudeck","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0825","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.coesh.2020.09.002","article-title":"Biosurfactants and anti-inflammatory activity: A potential new approach towards COVID-19","volume":"17","author":"Subramaniam","year":"2020","journal-title":"Curr. Opin. Environ. Sci. Health"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0830","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/v14020189","article-title":"Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection","volume":"14","author":"Tamir","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0835","first-page":"339","article-title":"Coronavirus COV-19\/SARS-CoV-2 affects women less than men: clinical response to viral infection","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0840","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb0845","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4049\/jimmunol.1800927","article-title":"Critical adverse impact of IL-6 in acute pneumovirus infection","volume":"202","author":"Percopo","year":"2019","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.137836_bb0850","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/jmv.25987","article-title":"In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs","volume":"92","author":"Choudhury","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0855","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1556\/030.65.2018.028","article-title":"DNA microarray technology and bioinformatic web services","volume":"66","author":"Behzadi","year":"2019","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0860","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2174\/1874285801711010330","article-title":"DNA microarray for rapid detection and identification of food and water borne bacteria: from dry to wet lab","volume":"11","author":"Ranjbar","year":"2017","journal-title":"Open Microbiol. J."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0865","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41422-021-00495-9","article-title":"SARS-CoV-2 spike protein interacts with and activates TLR41","volume":"31","author":"Zhao","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0870","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e343","article-title":"COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis","volume":"35","author":"Sohn","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.137836_bb0875","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102763","article-title":"The role of epithelial damage in the pulmonary immune response","volume":"10","author":"Burgoyne","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06187","article-title":"SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages","volume":"7","author":"Shirato","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0885","first-page":"3376","article-title":"Effect of TLR4\/MyD88 signaling pathway on sepsis-associated acute respiratory distress syndrome in rats, via regulation of macrophage activation and inflammatory response","volume":"15","author":"Zhou","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0890","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7527953","article-title":"Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment","volume":"2020","author":"Cicco","year":"2020","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0895","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0900","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124082","article-title":"Respiratory syncytial virus fusion protein promotes TLR-4\u2013dependent neutrophil extracellular trap formation by human neutrophils","volume":"10","author":"Funchal","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11249-y","article-title":"Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0910","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ajpath.2011.03.013","article-title":"Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis","volume":"179","author":"Narasaraju","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0915","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00430-009-0121-x","article-title":"The clinical value of neutrophil extracellular traps","volume":"198","author":"L\u00f6gters","year":"2009","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0920","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41590-021-00937-x","article-title":"TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines","volume":"22","author":"Zheng","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0925","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1556\/030.64.2017.008","article-title":"Advances in diagnosis and treatment of Helicobacter pylori infection","volume":"64","author":"Ranjbar","year":"2017","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0930","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.clinthera.2016.02.028","article-title":"Key role of DAMP in inflammation, cancer, and tissue repair","volume":"38","author":"Pandolfi","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0935","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140105","article-title":"Mitochondrial damage-associated molecular patterns (MTDs) are released during hepatic ischemia reperfusion and induce inflammatory responses","volume":"10","author":"Hu","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0940","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368946","article-title":"TLR2\/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells","volume":"15","author":"Landolina","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0945","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s44298-024-00038-0","article-title":"Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1","volume":"2","author":"Lathrop","year":"2024","journal-title":"npj Viruses"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0950","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-59405-9","article-title":"SARS-CoV-2 infection activates inflammatory macrophages in vascular immune organoids","volume":"14","author":"Chau","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41479-023-00121-9","article-title":"Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients","volume":"16","author":"Houssen","year":"2024","journal-title":"Pneumonia (Nathan Qld.)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb0960","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jleuko\/qiad111","article-title":"TLR4 sensitizes plasmacytoid dendritic cells for antiviral response against SARS-CoV-2 coronavirus","volume":"115","author":"Lim","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0965","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jinf.2022.11.022","article-title":"No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis","volume":"86","author":"Cheema","year":"2023","journal-title":"J. Infect."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0970","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150542","article-title":"SARS-CoV-2\u2013associated ssRNAs activate inflammation and immunity via TLR7\/8","volume":"6","author":"Salvi","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0975","first-page":"9","article-title":"Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy","volume":"34","author":"Kritas","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0980","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/jmv.26826","article-title":"Role of toll-like receptors in the pathogenesis of COVID-19","volume":"93","author":"Khanmohammadi","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0985","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0990","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41422-020-0327-4","article-title":"COVID-19: towards understanding of pathogenesis","volume":"30","author":"Cao","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb0995","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1000","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/vim.2020.0074","article-title":"Toll-like receptor antagonists as a potential therapeutic strategy against cytokine storm in COVID-19-infected patients","volume":"34","author":"Safaei","year":"2021","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1005","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67569","article-title":"Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study","volume":"10","author":"Fallerini","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41435-021-00157-1","article-title":"Rare variants in toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients","volume":"23","author":"Mantovani","year":"2022","journal-title":"Genes Immun."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O\u2019Driscoll","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2021.719115","article-title":"Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19","volume":"12","author":"Solanich","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1030","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1136\/annrheumdis-2020-218100","article-title":"Presence of antiphospholipid antibodies in COVID-19: a case series study","volume":"80","author":"Amezcua-Guerra","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584241","article-title":"Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome","volume":"11","author":"Borghi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41590-021-01123-9","article-title":"Immunology of SARS-CoV-2 infection in children","volume":"23","author":"Chou","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1045","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12895","article-title":"SARS-CoV-2 infection-induced immune responses: friends or foes?","volume":"92","author":"Li","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","article-title":"Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children","volume":"40","author":"Loske","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1055","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1016\/j.molcel.2021.04.008","article-title":"Functional landscape of SARS-CoV-2 cellular restriction","volume":"81","author":"Martin-Sancho","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102295","article-title":"SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway","volume":"24","author":"Campbell","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1070","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114150","article-title":"Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19","volume":"13","author":"Theobald","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41423-020-00602-7","article-title":"Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors","volume":"18","author":"Onomoto","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1080","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1002\/jmv.27050","article-title":"SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I\/MDA-5\u2013MAVS, TLR3\u2013TRIF, and cGAS\u2013STING signaling pathways","volume":"93","author":"Han","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114316","article-title":"Detection of viral infections by innate immunity","volume":"183","author":"Carty","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2021.11.002","article-title":"Host cell-intrinsic innate immune recognition of SARS-CoV-2","volume":"52","author":"Madden","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1095","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1100","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/molecules27030658","article-title":"Approaches to the potential therapy of COVID-19: a general overview from the medicinal chemistry perspective","volume":"27","author":"Men\u00e9ndez","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1115","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-021-05691-x","article-title":"COVID-19 and the clinical course of rheumatic manifestations","volume":"40","author":"Ahmed","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107087","article-title":"Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets","volume":"89","author":"Kumar","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1125","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/jmv.27405","article-title":"Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19","volume":"94","author":"Manik","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.arcmed.2020.04.021","article-title":"COVID-19: developing from an outbreak to a pandemic","volume":"51","author":"Hanaei","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1135","article-title":"SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120686","article-title":"Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines?","volume":"603","author":"Tiboni","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41392-021-00686-1","article-title":"SARS-CoV-2-specific immune response in COVID-19 convalescent individuals","volume":"6","author":"Pan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1155","series-title":"Coronavirus Therapeutics\u2013Volume I: Basic Science and Therapy Development","first-page":"87","article-title":"Toll-like receptors (TLRs) as therapeutic targets for treating SARS-CoV-2: An immunobiological perspective","author":"Patra","year":"2022"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1160","doi-asserted-by":"crossref","DOI":"10.2196\/23026","article-title":"Learning from past respiratory infections to predict COVID-19 outcomes: retrospective study","volume":"23","author":"Sang","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1165","first-page":"10","article-title":"Identification of hospitalized mortality of COVID-19 patients by machine learning models based on blood inflammatory cytokines","volume":"4334","author":"Yu","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1170","article-title":"Hydroxychloroquine effects on TLR signalling: underexposed but unneglectable in COVID-19","volume":"2021","author":"Aliede","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fvl-2020-0342","article-title":"Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach","volume":"16","author":"Choudhury","year":"2021","journal-title":"Future Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2022.118633","article-title":"Designing AbhiSCoVac-A single potential vaccine for all \u2018corona culprits\u2019: Immunoinformatics and immune simulation approaches","volume":"351","author":"Choudhury","year":"2022","journal-title":"J. Mol. Liq."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb1190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines4020012","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.137836_bb1195","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acsnano.3c09700","article-title":"Nanoparticle-conjugated toll-like receptor 9 agonists improve the potency, durability, and breadth of COVID-19 vaccines","volume":"18","author":"Ou","year":"2024","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.137836_bb1200","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: A case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb1210","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.ijbiomac.2024.137836_bb1215","doi-asserted-by":"crossref","first-page":"13428","DOI":"10.1073\/pnas.2001569117","article-title":"Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics","volume":"117","author":"Buss","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb1220","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.17449","article-title":"Nucleic acid-based approaches for detection of viral hepatitis","volume":"8","author":"Behzadi","year":"2014","journal-title":"Jundishapur J. Microbiol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.137836_bb1225","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.bioconjchem.6b00370","article-title":"Thermoresponsive polymer nanoparticles co-deliver RSV F trimers with a TLR-7\/8 adjuvant","volume":"27","author":"Francica","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.137836_bb1230","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nbt.3371","article-title":"In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity","volume":"33","author":"Lynn","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.137836_bb1245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2019-0096","article-title":"Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases","volume":"12","author":"Fl\u00f3rez-\u00c1lvarez","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.756315","article-title":"Toll-like receptors as a therapeutic target in the era of immunotherapies","volume":"9","author":"Farooq","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1255","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1428713","article-title":"Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review","volume":"11","author":"Oboge","year":"2024","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1260","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/17534259211051364","article-title":"TLRs in COVID-19: how they drive immunopathology and the rationale for modulation","volume":"27","author":"Mabrey","year":"2021","journal-title":"Innate Immun."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1265","series-title":"Toll-like Receptors in Health and Disease","first-page":"1","article-title":"Toll-like receptors (TLRs) in health and disease: an overview","author":"Kumar","year":"2022"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1270","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/vaccines9090957","article-title":"COVID-19 subunit vaccine with a combination of TLR1\/2 and TLR3 agonists induces robust and protective immunity","volume":"9","author":"Jeong","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705080","article-title":"Targeting TLR4 signaling to blunt viral-mediated acute lung injury","volume":"12","author":"Shirey","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1280","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pro.4043","article-title":"Structural and functional understanding of the toll-like receptors","volume":"30","author":"Asami","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1285","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/acs.molpharmaceut.0c01256","article-title":"Toll-like receptor-4 (TLR4) agonist-based intranasal nanovaccine delivery system for inducing systemic and mucosal immunity","volume":"18","author":"Bakkari","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1290","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8874339","article-title":"COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation","volume":"2021","author":"Aboudounya","year":"2021","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10020-020-00172-4","article-title":"Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?","volume":"26","author":"Andersson","year":"2020","journal-title":"Mol. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01239","article-title":"Symptomatic protective action of glycyrrhizin (licorice) in COVID-19 infection?","volume":"11","author":"Murck","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1305","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejps.2019.04.016","article-title":"Aryl quinolinyl hydrazone derivatives as anti-inflammatory agents that inhibit TLR4 activation in the macrophages","volume":"134","author":"Debnath","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1310","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/fvl-2021-0171","article-title":"Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: an in silico study","volume":"17","author":"Das","year":"2022","journal-title":"Future Virol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1570180818666210901125519","article-title":"In silico identification of new anti-SARS-CoV-2 agents from bioactive phytocompounds targeting the viral spike glycoprotein and human TLR4","volume":"19","author":"Das","year":"2022","journal-title":"Lett. Drug Des. Discovery"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ph16010023","article-title":"Therapeutic targeting of TLR4 for inflammation, infection, and Cancer: A perspective for disaccharide lipid A mimetics","volume":"16","author":"Heine","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.629193","article-title":"SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients","volume":"12","author":"Olbei","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1335","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00109-021-02113-y","article-title":"The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis","volume":"99","author":"Bolourani","year":"2021","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108464","article-title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19","volume":"216","author":"Omarjee","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1345","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cytogfr.2020.09.002","article-title":"Is toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?","volume":"58","author":"Brandao","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1350","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2147\/JIR.S271768","article-title":"Coagulation disorders in COVID-19: role of toll-like receptors","author":"Biswas","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1355","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.1096\/fj.202001115R","article-title":"Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes","volume":"34","author":"Debnath","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1360","article-title":"mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19","volume":"20","author":"Ramaiah","year":"2020","journal-title":"Gene Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2021.103802","article-title":"Learning from past respiratory failure patients to triage COVID-19 patient ventilator needs: A multi-institutional study","volume":"119","author":"Carmichael","year":"2021","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1370","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145476","article-title":"SARS-CoV-2\u2013specific CD8+ T cell responses in convalescent COVID-19 individuals","volume":"131","author":"Kared","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1375","first-page":"1","article-title":"Toll-like receptor-mediated innate immunity against herpesviridae infection: A current perspective on viral infection signaling pathways","volume":"17","author":"Zheng","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1380","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2019.05.002","article-title":"Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir","volume":"168","author":"Georgel","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.601685","article-title":"TLR9 and COVID-19: a multidisciplinary theory of a multifaceted therapeutic target","volume":"11","author":"Bezemer","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1390","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1395","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8111704","article-title":"Coronavirus (SARS-CoV-2) pandemic: future challenges for dental practitioners","volume":"8","author":"Bordea","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158059","article-title":"SARS-CoV-2 infected pediatric cerebral cortical neurons: transcriptomic analysis and potential role of toll-like receptors in pathogenesis","volume":"22","author":"Gugliandolo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1405","series-title":"Use of a tlr9 Agonist in Methods for Treating Covid-19","author":"Chunduru","year":"2021"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1415","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810716","article-title":"Toll-like receptor mediation in SARS-CoV-2: a therapeutic approach","volume":"23","author":"Manan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1420","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/antib12010004","article-title":"TLR7 and IgM: dangerous partners in autoimmunity","volume":"12","author":"Amendt","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1425","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1430","series-title":"Identification of SARS-COV2 Spike Glycoprotein Epitope Amino Acid Sequences Recognized by Human Class II Antigen Presenting Determinant HLA-DR1 and Innate Immune Responder Toll-Like Receptor 8 by Using Computer Modeling and Molecular Docking Methods","author":"Dasgupta","year":"2022"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1435","unstructured":"NCT04448756."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1440","unstructured":"NCT04341935."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1515","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10787-021-00911-x","article-title":"Anti-inflammatory and anti-COVID-19 effect of a novel polyherbal formulation (Imusil) via modulating oxidative stress, inflammatory mediators and cytokine storm","volume":"30","author":"Ratheesh","year":"2022","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1520","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s43088-023-00420-6","article-title":"Efficacy of polyherbal formulation along with standard care of treatment in early recovery of COVID-19 patients: a randomized placebo-controlled trial","volume":"12","author":"Arun","year":"2023","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb1525","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/2045-9912.325991","article-title":"Effects of Iranian Polyherbal syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial","volume":"12","author":"Borujerdi","year":"2022","journal-title":"Med. Gas Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1530","article-title":"Herbal constituents of AYUSH-64 formulation modulate release of cytokines in TLR7\/8-induced macrophage-like cells","volume":"13","author":"Priya","year":"2023","journal-title":"J. Clin. Exp. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114738","article-title":"Anti-inflammatory effect of Kaba Sura Kudineer (AYUSH approved COVID-19 drug)-A siddha poly-herbal formulation against lipopolysaccharide induced inflammatory response in RAW-264.7 macrophages cells","volume":"283","author":"Jose","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1540","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05583-0","volume":"22","author":"Natarajan","year":"2021","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.137836_bb1545","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaim.2018.02.139","article-title":"Scientific validation of anti-arthritic effect of Kashayams - A polyherbal formulation in collagen induced arthritic rats","volume":"12","author":"I.S.","year":"2021","journal-title":"J. Ayurveda Integr. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1550","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-020-2097-2","article-title":"Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug","volume":"22","author":"Samarpita","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1555","article-title":"A comparative study of spike protein of SARS-CoV-2 and its variant omicron (B.1.1.529) on some immune characteristics","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1560","doi-asserted-by":"crossref","DOI":"10.1002\/ame2.12472","article-title":"Fevogrit, a polyherbal medicine, mitigates endotoxin (lipopolysaccharide)-induced fever in Wistar rats by regulating pro-inflammatory cytokine levels","author":"Balkrishna","year":"2024","journal-title":"Anim. Models Exp. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.137836_bb1565","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13275","article-title":"Role of toll-like receptors in the pathogenesis of COVID-19: current and future perspectives","volume":"98","author":"Yang","year":"2023","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb1570","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s13577-021-00510-6","article-title":"Association of TLR3 functional variant (rs3775291) with COVID-19 susceptibility and death: a population-scale study","volume":"34","author":"Dhangadamajhi","year":"2021","journal-title":"Hum. Cell"},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.137836_bb1575","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1080\/15548627.2021.1995152","article-title":"The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males","volume":"18","author":"Croci","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1580","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.2147\/JIR.S343246","article-title":"Toll-like receptor 4 polymorphisms (896A\/G and 1196C\/T) as an Indicator of COVID-19 severity in a convenience sample of Egyptian patients","volume":"14","author":"Taha","year":"2021","journal-title":"J. Inflamm. Res."},{"issue":"62","key":"10.1016\/j.ijbiomac.2024.137836_bb1585","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.137836_bb1590","first-page":"71","article-title":"TLR8 is highly conserved among the Saudi population and its mutations have no effect on the severity of COVID-19 symptoms","volume":"10","author":"Mahallawi","year":"2021","journal-title":"Am. J. Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.137836_bb1595","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/1750743X.2024.2360382","article-title":"Helminth-derived biomolecules as potential therapeutics against ulcerative colitis","volume":"16","author":"Chakraborty","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1600","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1394953","article-title":"Molecular mechanisms and therapeutic possibilities of short-chain fatty acids in posttraumatic stress disorder patients: a mini-review","volume":"18","author":"Petakh","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1605","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ni.1828","article-title":"Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21","volume":"11","author":"Sheedy","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1610","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri3151","article-title":"Accessory molecules for toll-like receptors and their function","volume":"12","author":"Lee","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1615","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.celrep.2018.11.081","article-title":"Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands","volume":"25","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009885","article-title":"Current status of therapeutic monoclonal antibodies against SARS-CoV-2","volume":"17","author":"Kumar","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1625","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1630","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1640","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2021.100085","article-title":"The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review","volume":"10","author":"Das","year":"2021","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1645","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/TCRM.S301817","article-title":"Chloroquine and hydroxychloroquine for the prevention and treatment of COVID-19: A fiction, hope or hype? An updated review","volume":"17","author":"Saghir","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1650","doi-asserted-by":"crossref","DOI":"10.1097\/j.pbj.0000000000000132","article-title":"Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment","volume":"6","author":"Ehianeta","year":"2021","journal-title":"Porto Biomed. J."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1655","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/acschembio.1c00756","article-title":"Clinical antiviral drug arbidol inhibits infection by SARS-CoV-2 and variants through direct binding to the spike protein","volume":"16","author":"Shuster","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015874","article-title":"Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol","volume":"6","author":"Teissier","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1665","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/iid3.502","article-title":"Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis","volume":"9","author":"Amani","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-77700-z","article-title":"Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir","volume":"10","author":"Bolcato","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1675","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials","volume":"14","author":"Patel","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1685","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/acscentsci.0c01242","article-title":"Modeling the binding mechanism of remdesivir, favilavir, and ribavirin to SARS-CoV-2 RNA-dependent RNA polymerase","volume":"7","author":"Byl\u00e9hn","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1690","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M20-8148","article-title":"Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians practice points","volume":"174","author":"Kaka","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1695","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1700","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1705","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14787210.2021.1866545","article-title":"A review on favipiravir: the properties, function, and usefulness to treat COVID-19","volume":"19","author":"Hashemian","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1715","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1720","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1725","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-021-03667-0","article-title":"Merck's COVID pill loses its lustre: what that means for the pandemic","author":"Kozlov","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1730","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/DDDT.S94165","article-title":"Plitidepsin: design, development, and potential place in therapy","volume":"11","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1735","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.abf4058","article-title":"Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A","volume":"371","author":"White","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1740","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/jpm11070668","article-title":"Plitidepsin: mechanisms and clinical profile of a promising antiviral agent against COVID-19","volume":"11","author":"Papapanou","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1745","article-title":"Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization","author":"Varona","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1750","first-page":"1","article-title":"Global trends in clinical studies of ivermectin in COVID-19","volume":"74","author":"Yagisawa","year":"2021","journal-title":"Jpn. J. Antibiot."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1755","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000001402","article-title":"Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines","volume":"28","author":"Bryant","year":"2021","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1760","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41591-021-01535-y","article-title":"The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable","volume":"27","author":"Lawrence","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1765","first-page":"1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1770","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1775","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1038\/s41366-020-00689-y","article-title":"Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections","volume":"44","author":"Schlicht","year":"2020","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1780","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110111","article-title":"Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin","volume":"143","author":"Mozafari","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ijbiomac.2024.137836_bb1785","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41598-021-04511-1","article-title":"Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection","volume":"12","author":"Guardado-Mendoza","year":"2022","journal-title":"Sci. Rep."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302408646X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302408646X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:51:14Z","timestamp":1734025874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014181302408646X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":340,"alternative-id":["S014181302408646X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.137836","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dual role of toll-like receptors in COVID-19: Balancing protective immunity and immunopathogenesis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.137836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"137836"}}